|
[1]
|
NK Cells in Cancer Immunotherapy: Successes and Challenges
2023
DOI:10.1016/B978-0-12-822620-9.00010-0
|
|
|
|
|
[2]
|
The Role of NKG2D and Its Ligands in Autoimmune Diseases: New Targets for Immunotherapy
International Journal of Molecular Sciences,
2023
DOI:10.3390/ijms242417545
|
|
|
|
|
[3]
|
Increased Concentrations of Circulating Soluble MHC Class I-Related Chain A (sMICA) and sMICB and Modulation of Plasma Membrane MICA Expression: Potential Mechanisms and Correlation With Natural Killer Cell Activity in Systemic Lupus Erythematosus
Frontiers in Immunology,
2021
DOI:10.3389/fimmu.2021.633658
|
|
|
|
|
[4]
|
A subgroup of lupus patients with nephritis, innate T cell activation and low vitamin D is identified by the enhancement of circulating MHC class I-related chain A
Clinical and Experimental Immunology,
2019
DOI:10.1111/cei.13273
|
|
|
|
|
[5]
|
NKG2D and Its Ligand MULT1 Contribute to Disease Progression in a Mouse Model of Multiple Sclerosis
Frontiers in Immunology,
2019
DOI:10.3389/fimmu.2019.00154
|
|
|
|
|
[6]
|
NKG2D‐ligands: Putting everything under the same umbrella can be misleading
HLA,
2018
DOI:10.1111/tan.13246
|
|
|
|
|
[7]
|
NKG2D-ligands: Putting everything under the same umbrella can be misleading
HLA,
2018
DOI:10.1111/tan.13246
|
|
|
|
|
[8]
|
Natural Killer Cells: Development, Maturation, and Clinical Utilization
Frontiers in Immunology,
2018
DOI:10.3389/fimmu.2018.01869
|
|
|
|
|
[9]
|
The Paradoxical Role of NKG2D in Cancer Immunity
Frontiers in Immunology,
2018
DOI:10.3389/fimmu.2018.01808
|
|
|
|
|
[10]
|
Bystander T Cells: A Balancing Act of Friends and Foes
Trends in Immunology,
2018
DOI:10.1016/j.it.2018.10.003
|
|
|
|